CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis

Anna Laura Fedele, Stefano Alivernini, Elisa Gremese, Gianfranco Ferraccioli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

4 Citazioni (Scopus)

Abstract

We describe a patient suffering from seropositive rheumatoid arthritis (RA) and type I diabetes mellitus (T1DM), who achieved a good EULAR response together with an improvement of the glycemic profile under treatment with CTLA-4 Ig. A close association is known to exist between T1DM and RA, and CTLA-4 exon 1 polymorphism has been associated to RA with coexisting autoimmune endocrinopathies. The possible common genetic background and the potential role of CTLA-4 Ig in the early phases of T1DM, could be considered in the therapeutic interventions in RA patients with type 1 diabetes.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaClinical and Experimental Rheumatology
Stato di pubblicazionePubblicato - 2015

Keywords

  • CTLA-4
  • rheumatoid arthritis

Fingerprint

Entra nei temi di ricerca di 'CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis'. Insieme formano una fingerprint unica.

Cita questo